Literature DB >> 33190475

Structure-Based Design of Melanocortin 4 Receptor Ligands Based on the SHU-9119-hMC4R Cocrystal Structure†.

Charlotte Martin1, Luis E Gimenez2, Savannah Y Williams2, Yu Jing3, Yiran Wu3, Charlie Hollanders1, Olivier Van der Poorten1, Simon Gonzalez1, Kevin Van Holsbeeck1, Santo Previti1, Arthur Lamouroux1, Suwen Zhao3,4, Dirk Tourwé1, Raymond C Stevens3,4, Roger D Cone2,5, Steven Ballet1.   

Abstract

The melanocortin receptors (MC1R-MC5R) belong to class A G-protein-coupled receptors (GPCRs) and are known to have receptor-specific roles in normal and diseased states. Selectivity for MC4R is of particular interest due to its involvement in various metabolic disorders, including obesity, feeding regulation, and sexual dysfunctions. To further improve the potency and selectivity of MC4R (ant)agonist peptide ligands, we designed and synthesized a series of cyclic peptides based on the recent crystal structure of MC4R in complex with the well-characterized antagonist SHU-9119 (Ac-Nle4-c[Asp5-His6-DNal(2')7-Arg8-Trp9-Lys10]-NH2). These analogues were pharmacologically characterized in vitro, giving key insights into exploiting binding site subpockets to deliver more selective ligands. More specifically, the side chains of the Nle4, DNal(2')7, and Trp9 residues in SHU-9119, as well as the amide linkage between the Asp5 and Lys10 side chains, were found to represent structural features engaging a hMC4R/hMC3R selectivity switch.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33190475     DOI: 10.1021/acs.jmedchem.0c01620

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  When Macrocyclic Peptides Meet the Crystal Structure of a Melanocortin Receptor.

Authors:  Paolo Grieco
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

2.  Demonstration of a Common DPhe7 to DNal(2')7 Peptide Ligand Antagonist Switch for Melanocortin-3 and Melanocortin-4 Receptors Identifies the Systematic Mischaracterization of the Pharmacological Properties of Melanocortin Peptides.

Authors:  Luis E Gimenez; Terry A Noblin; Savannah Y Williams; Satarupa Mullick Bagchi; Ren-Lei Ji; Ya-Xiong Tao; Claus B Jeppesen; Kilian W Conde-Frieboes; Tomi K Sawyer; Paolo Grieco; Roger D Cone
Journal:  J Med Chem       Date:  2022-04-11       Impact factor: 7.446

3.  Development of Reduced Peptide Bond Pseudopeptide Michael Acceptors for the Treatment of Human African Trypanosomiasis.

Authors:  Santo Previti; Roberta Ettari; Carla Di Chio; Rahul Ravichandran; Marta Bogacz; Ute A Hellmich; Tanja Schirmeister; Sandro Cosconati; Maria Zappalà
Journal:  Molecules       Date:  2022-06-11       Impact factor: 4.927

4.  Bifunctional Opioid/Melanocortin Peptidomimetics for Use in Neuropathic Pain: Variation in the Type and Length of the Linker Connecting the Two Pharmacophores.

Authors:  Ewa Witkowska; Magda Godlewska; Jowita Osiejuk; Sandra Gątarz; Beata Wileńska; Katarzyna Kosińska; Joanna Starnowska-Sokół; Anna Piotrowska; Piotr F J Lipiński; Joanna Matalińska; Jolanta Dyniewicz; Paweł K Halik; Ewa Gniazdowska; Barbara Przewlocka; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2022-01-08       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.